Provided herein are compounds that inhibit HDAC6, a protein whose activity is associated with a variety of diseases (e.g., cancer, neurological disorders). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating HDAC6-related diseases and disorders (e.g., Alzheimer's disease, cancer) with the compounds in a subject, by administering the compounds and/or compositions described herein.

The present disclosure provides compounds and methods useful for inhibiting SARM1 and/or treating and/or preventing neurodegenerative disease or axonal degeneration. The provided SARM1 inhibitors may reduce or inhibit binding of NAD+ by SARM1. Alternatively, provided SARM1 inhibitors bind to SARM1 within a pocket comprising one or more catalytic residues (e.g., a catalytic cleft of SARM1).

The present disclosure provides compounds and methods useful for inhibiting SARM1 and/or treating and/or preventing neurodegenerative disease or axonal degeneration. The provided SARM1 inhibitors may reduce or inhibit binding of NAD+ by SARM1. Alternatively, provided SARM1 inhibitors bind to SARM1 within a pocket comprising one or more catalytic residues (e.g., a catalytic cleft of SARM1).

An organic compound represented by formula [1]. The compounds are of the class of diacenaphthochrysene compound, useful as organic light emitting device. ##STR00001## In the formula [1], R.sub.1 to R.sub.18 are each independently selected from the group consisting of a hydrogen atom and a substituent.

An organic compound represented by formula [1]. The compounds are of the class of diacenaphthochrysene compound, useful as organic light emitting device. ##STR00001## In the formula [1], R.sub.1 to R.sub.18 are each independently selected from the group consisting of a hydrogen atom and a substituent.

An organic compound represented by formula [1]. The compounds are of the class of diacenaphthochrysene compound, useful as organic light emitting device.

##STR00001##

In the formula [1], R.sub.1 to R.sub.18 are each independently selected from the group consisting of a hydrogen atom and a substituent.

An organic compound represented by formula [1]. The compounds are of the class of diacenaphthochrysene compound, useful as organic light emitting device.

##STR00001##

In the formula [1], R.sub.1 to R.sub.18 are each independently selected from the group consisting of a hydrogen atom and a substituent.

Fused bicyclic compounds are inhibitors of GPR91. The compounds, their stereoisomers, tautomers, prodrugs, polymorphs, solvates, pharmaceutically acceptable salts, and pharmaceutical compositions containing them are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of GPR91.

Fused bicyclic compounds are inhibitors of GPR91. The compounds, their stereoisomers, tautomers, prodrugs, polymorphs, solvates, pharmaceutically acceptable salts, and pharmaceutical compositions containing them are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of GPR91.

The present invention relates to dihydro-cyclopenta-isoquinoline derivatives of formula (I): processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular, disorders caused by the interaction of IgE with the Fc?RI receptor.

##STR00001##